Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Clinical Study to Investigate the Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of BTK Inhibitor BGB-3111 in Chinese Patients With B-cell Lymphoma

NCT03189524 is registered in ClinicalTrials.gov with BeiGene as lead sponsor.

NCT NCT03189524
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03189524 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Clinical Study to Investigate the Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of BTK Inhibitor BGB-3111 in Chinese Patients With B-cell Lymphoma
Lead sponsor
BeiGene
Phase
Phase 1
Overall status
Completed
Start date
July 5, 2016
Completion date
August 26, 2020
Enrollment
44 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

b-cell lymphoma